Cohance Lifesciences Ltd

Cohance Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cohance Lifesciences Ltd

₹ 881 -1.94%
26 Aug - close price
suvenpharm.com BSE: 543064 NSE: COHANCE
About

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

Key Points

Market Position
The company has established a strong presence in the contract research and manufacturing services (CRAMS) sector and is one of the top 5 providers of high-end intermediates to innovators in India. [1]

Website BSE NSE
  • Market Cap ₹ 33,698 Cr.
  • Current Price ₹ 881
  • High / Low ₹ 1,360 / 878
  • Stock P/E 95.8
  • Book Value ₹ 66.6
  • Dividend Yield 0.00 %
  • ROCE 33.0 %
  • ROE 26.6 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is expected to give good quarter
  • Promoter holding has increased by 16.3% over last quarter.
  • Company's working capital requirements have reduced from 90.2 days to 55.9 days

Cons

  • Stock is trading at 13.2 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoters have pledged or encumbered 100% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty MNC

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
339 278 354 369 348 231 220 253 488 258 307 840 549
188 179 207 198 181 133 154 180 363 154 189 611 437
Operating Profit 151 100 147 172 167 98 66 73 125 104 118 229 112
OPM % 45% 36% 41% 47% 48% 42% 30% 29% 26% 40% 38% 27% 20%
11 11 13 11 11 20 14 17 19 14 16 -4 6
Interest 1 0 1 5 1 0 2 2 10 2 3 10 10
Depreciation 12 12 12 12 13 12 13 17 31 17 20 54 45
Profit before tax 149 98 146 166 164 105 65 71 103 100 110 161 63
Tax % 28% 27% 26% 25% 26% 25% 29% 25% 27% 18% 24% 27% 26%
108 72 108 124 121 80 47 53 75 82 83 117 46
EPS in Rs 4.22 2.83 4.23 4.87 4.74 3.13 1.84 2.10 2.96 3.23 3.26 4.73 1.28
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
378 834 1,010 1,320 1,340 1,051 2,608 1,955
206 449 567 738 766 645 1,811 1,392
Operating Profit 172 385 443 582 574 406 797 563
OPM % 45% 46% 44% 44% 43% 39% 31% 29%
1 66 68 133 46 62 53 32
Interest 3 23 12 9 13 7 41 26
Depreciation 12 24 32 39 48 55 167 137
Profit before tax 158 405 468 668 560 406 643 433
Tax % 31% 22% 23% 32% 27% 26% 25%
109 317 362 454 411 300 484 329
EPS in Rs 12.45 14.23 17.83 16.16 11.80 19.14 12.50
Dividend Payout % 0% 20% 14% 28% 37% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 26%
3 Years: 25%
TTM: 64%
Compounded Profit Growth
10 Years: %
5 Years: 10%
3 Years: 7%
TTM: 38%
Stock Price CAGR
10 Years: %
5 Years: 21%
3 Years: 25%
1 Year: -17%
Return on Equity
10 Years: %
5 Years: 25%
3 Years: 22%
Last Year: 27%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.00 13 25 25 25 25 25
Reserves 578 832 1,155 1,502 1,710 2,025 1,671
83 186 143 97 70 65 279
123 142 151 205 160 138 1,056
Total Liabilities 783 1,173 1,474 1,830 1,966 2,254 3,032
271 357 441 534 663 670 1,714
CWIP 111 102 96 30 165 179 255
Investments 7 338 542 598 536 904 337
394 376 395 667 601 501 726
Total Assets 783 1,173 1,474 1,830 1,966 2,254 3,032

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
50 407 383 330 457 358 288
-65 -413 -311 -136 -195 -362 -255
26 7 -76 -156 -242 -14 3
Net Cash Flow 11 1 -5 37 20 -18 36

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 142 51 37 65 30 46 40
Inventory Days 556 278 243 259 279 268 74
Days Payable 190 113 100 97 63 49 36
Cash Conversion Cycle 509 217 180 228 247 265 78
Working Capital Days 205 64 56 108 99 115 56
ROCE % 50% 40% 41% 32% 19% 33%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 50.10% 50.10% 50.10% 50.10% 50.10% 66.41%
7.58% 8.11% 9.47% 9.50% 10.01% 10.14% 9.54% 9.80% 10.70% 10.84% 11.05% 7.23%
10.87% 11.36% 11.43% 10.63% 14.13% 15.94% 17.24% 17.42% 16.95% 16.67% 16.60% 11.40%
0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
21.56% 20.55% 19.10% 19.88% 15.85% 13.93% 23.11% 22.67% 22.26% 22.37% 22.24% 14.95%
No. of Shareholders 82,57779,41272,88572,16773,71570,05268,93265,77769,33784,21086,32580,910

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls